Osel is a pioneering brand in the field of Live Biotherapeutic Products (LBPs). With a mission to develop and commercialize a diverse portfolio of LBPs, Osel aims to prevent or treat abnormal conditions caused by disruptions in the human microbiome. Since filing its first IND with the FDA in 2003, Osel has been at the forefront of LBP research and development.

The core focus of Osel's work is women's health, specifically indications such as bacterial vaginosis, obstetric complications, and recurrent urinary tract infections. The brand also has a keen interest in gastrointestinal tract disorders and oncology. Osel's innovative approach to treating dysbiosis involves repopulating the microbiome with beneficial bacteria to restore a healthy and protective microbiota.

With two clinical stage products and ongoing trials, Osel's product pipeline shows exciting therapeutic potential. Led by a team of experienced professionals, including Founder and Executive Chairman Dr. Peter P.

Lee, Director of Research Dr. Laurel A. Lagenaur, and Director of Product Development Dr.

Tom Parks, Osel is committed to translating cutting-edge research into impactful commercial products. Supported by a dedicated board and renowned scientific advisors, including Dr. Craig Cohen and Dr.

Gary Schoolnik, Osel is positioned to make significant contributions to the field of LBPs and advance the understanding and treatment of various health conditions related to the human microbiome